Cell Therapy

Trauma surgeons often face a race against time when a patient presents with a shattered limb or a ruptured artery where every second spent searching for a viable donor vein increases the risk of amputation or death. This high-pressure environment has long necessitated a surgical solution that

The fundamental shift in managing Diffuse Large B-cell Lymphoma has transitioned from standardized salvage chemotherapy to a highly personalized approach utilizing engineered immune cells that target cancer with surgical precision. For decades, the therapeutic trajectory for patients who did not

The South Korean government has officially introduced a bold strategic roadmap to transform its medical sector through the 2nd Basic Plan for Advanced Regenerative Medicine and Advanced Biopharmaceuticals. This five-year initiative, spanning the period from 2026 to 2030, aims to establish a

The landscape of oncology has reached a pivotal juncture where terminal diagnoses for aggressive blood cancers are increasingly being redefined by the success of durable, long-term immunotherapy outcomes. Recent five-year clinical data for lisocabtagene maraleucel, commonly referred to as liso-cel,

Ivan Kairatov is a seasoned Biopharma expert with a distinguished career in research and development, specializing in the technological innovations that drive drug discovery. His deep understanding of protein dynamics and structural biology makes him a leading voice in deciphering the complex

The rapid evolution of therapeutic interventions in the oncology sector has necessitated a fundamental shift in how clinical success is quantified, moving beyond immediate tumor shrinkage toward a comprehensive evaluation of patient outcomes over several years. Historically, the primary metrics for